Skip to content

Prognositic Evaluation Technique for Oral Cancer: Construction of Prognositic Evaluation Model for Oral Cancer Based on Clinico-Pathological, Microbiome and Trascriptome Characteristics

Prognositic Evaluation Technique for Oral Cancer: Construction of Prognositic Evaluation Model for Oral Cancer Based on Clinico-Pathological, Microbiome and Trascriptome Characteristics

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100041975
Enrollment
Unknown
Registered
2021-01-10
Start date
2021-08-01
Completion date
Unknown
Last updated
2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Squamous Cell Carcinoma

Interventions

Study Cohort:N/A

Sponsors

Stomatological Hospital of Shandong
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Patients with age 18-75 years old, regardless of gender; (2) Patients with primary oral cancer, and first virst for the tumor; (3) Patients with tumors histologically confirmed as squamous cell carcinoma; (4) Patients with tumors at: tongue body, floor of mouth, gums, buccal mucosa, hard palate and posterior molar area; (5) Patients with good general conditions that could tolerant the treatment, without contraindications of operations; (6) Patients voluntarily paticipate in the program and sign the consent forms.

Exclusion criteria

Exclusion criteria: (1) Patients with histories of oral cancer and other maliganancies; (2) Patients with histories of operations, chemoradiotherapies, laser, immunotherapies or Chinese traditional therapies before visit; (3) Patients with distant metastasis (confirmed by pulmonary CT, or ultrasound of liver, gallbladder, pancreas, spleen, kidney, abdomen); (4) Patients refuse to undertake operations; (5) Patients with poor general conditions that can not tolerant operations (based on routine examinations, such as blood biochemical exams, ECG, chest X-ray etc); (6) Patients have continuously used antibiotics or immune agents for 2 weeks within 3 months; (7) Patients with severe immunodificency (such as AIDS) or general autoimmune disease (such as SLE); (8) Patients with severe sysmetic disease (such as severe disfuntion of hear, chest, liver or kidney); (9) Preganancy women (18-49 years old childbearing age women with positive preganancy test within 7 days) or lactation women, or others could not take contraceptive measures during the program; (10) Other conditions considered inappropriate by the researcher.

Design outcomes

Primary

MeasureTime frame
Sensitivity;Specificity;AUC of ROC;

Secondary

MeasureTime frame
Overall Survival;Disease Free Survival;Microbiome Change;Transcriptome Change;

Countries

China

Contacts

Public ContactYu Dou

Stomatological Hospital of Shandong

yu.dou@sdu.edu.cn+86 18678805870

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026